View Exam | PowerPak

1. Which of the following do patients with AA identify as being the most significantly impacted by their hair loss?

A. Attendance at work/school B. Interpersonal relationships C. Self-confidence

2. JAK inhibitor treatment is associated with achievement of ≤20% scalp hair loss (SALT ≤20%) in approximately what percentage of patients with AA?

A. <20% B. 20 to 30% C. 30 to 40%

3. Kaleigh is a 23-year-old woman with severe AA who began treatment with a JAK inhibitor 6 weeks ago and has requested a prescription refill. At the time of her request, she mentions that she has had persistent cold symptoms (nasopharyngitis) over the last 2 weeks. Which of the following would you do prior to completing the refill?

A. Inform the patient that nasopharyngitis is a common side effect of the medication B. Advise the patient that cold symptoms are unlikely to be related to the medication and recommend OTC treatment for cold symptoms C. Advise the patient to stop taking the medication immediately

4. The potential place of emerging therapies for AA will be influenced by their potential to positively impact the cost of AA care over the long-term. How do current healthcare utilization costs among patients with AA compare with patients who do not have AA?

A. No significant difference in costs B. 15% greater costs C. 35% greater costs

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following do patients with AA identify as being the most significantly impacted by their hair loss?

2. JAK inhibitor treatment is associated with achievement of ≤20% scalp hair loss (SALT ≤20%) in approximately what percentage of patients with AA?

4. The potential place of emerging therapies for AA will be influenced by their potential to positively impact the cost of AA care over the long-term. How do current healthcare utilization costs among patients with AA compare with patients who do not have AA?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following do patients with AA identify as being the most significantly impacted by their hair loss?

2. JAK inhibitor treatment is associated with achievement of ≤20% scalp hair loss (SALT ≤20%) in approximately what percentage of patients with AA?

4. The potential place of emerging therapies for AA will be influenced by their potential to positively impact the cost of AA care over the long-term. How do current healthcare utilization costs among patients with AA compare with patients who do not have AA?

« Return to Activity

Customers who Purchased
this Activity also Purchased